# US 2003/0229392 A1 · Drug eluted vascular graft

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229392 A1
- Document ID: US20030229392A1
- Status: Published application
- Kind: A1
- Application number: 10/443,722
- Filed: 2003-05-23
- Published: 2003-12-11
- Earliest claimed: 2002-06-03
- Inventors: Samuel J. Wong
- Web page: https://patentgrep.com/patent/US20030229392A1

## CPC

- A61M 1/3655: {Arterio-venous shunts or fistulae}
- A61F 2/06: Blood vessels
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61M 1/3672: {Means preventing coagulation}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

A drug Eluted vascular graft where the internal lumen are coated with at least one or more bioerodible polymers capable of releasing at least one or more therapeutic agents in a controlled time-released manner. The therapeutic agent may include an antimicrotubule, an antiproliferative agent, or an antithrombogenic agent. A method for preventing thrombosis of vascular grafts used in vascular access for hemodialysis, vascular reconstruction and coronary bypass grafting.

## Claims

### Claim 1

A drug eluting vascular graft for the controlled and sustained delivery of at least one therapeutic agent within the internal lumen of the vascular graft.

### Claim 2 (depends on 1)

The drug eluting vascular graft of claim 1, wherein said vascular graft is composed of at least one or more drug Eluted layers within the internal lumen of said graft.

### Claim 3 (depends on 1)

The drug eluting vascular graft of claim 1, wherein drug an eluted layer(s) is composed of at least one bioerodible, biocompatible, pharmaceutically acceptable polymer.

### Claim 4 (depends on 1)

The drug eluting vascular graft of claim 1, wherein microcapsules of one or more therapeutic agents are interspersed within said polymers.

### Claim at position 5 (depends on 1)

5 The drug eluting vascular graft of claim 1, wherein said vascular graft may be comprised of expanded polytetrafluroethylene (ePTFE), polyvinylchloride polypropylene, florinated ethylene propylene, polyetherurethaneura or other biocompatible plastics.

### Claim at position 6 (depends on 1)

6 The drug eluting vascular graft of claim 1, wherein said vascular graft may be of various diameters and lengths.

### Claim at position 7 (depends on 1)

7 The drug eluting vascular graft of claim 1, wherein at least one polymer is a polyester.

### Claim 8 (depends on 1)

The drug eluting vascular graft of claim 1, wherein at least polymer is of a pharmaceutically acceptable, biocompatible, bioerodible polymer comprising of mers I and II according to the following formula: ##STR1## wherein R.sub.1 is a member selected from the group consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; alkyleneoxy of 2 to 6 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene of 3 to 7 carbons substituted with a member selected form the group consisting of alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, and alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; cycloalkenylene of 4 to 7 carbons; cycloalkenylene of 4 to 7 carbons substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; arylene; and arylene substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, an alklene of 1 to 10 carbons, an alkenyl of 2 to 7 carbons; and wherein a is 0 to 1; b is 2 to 6; m is greater than 10; n is greater than 10; and at least one R.sub.1, a, and b in mer I is different that R.sub.1, a, and b in mer II; a drug present in the matrix; and (c) wherein the device when in operation bioerodes and releases drug at a rate selected from (1) a zero order rate, (2) a continuous rate, and (3) a variable rate, which rate is produced by preselecting the copolymer, the drug, and the geometric device to give the desired result.

### Claim 9 (depends on 1)

The drug eluting vascular graft of claim 1, wherein at least one polymer is of a hydrophobic, bioerodible, drug release rate controlling material, which material is comprising mers I, II, and III according to the following formula: ##STR2## wherein R.sub.1 is a member selected from the group consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; alkyleneoxy of 2 to 6 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene of 3 to 7 carbons substituted with a member selected from the group consisting of alkyl of 1 to 7 carbons, alkoxy of 1 to 7 carbons, and alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; cycloalkenylene of 4 to 7 carbons; cycloalkenylene of 4 to 7 carbons substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, and alkylene of 1 to 10 carbons, an alkenyl of 2 to 7 carbons; and wherein a is 0 to 1; b is 2 to 6; m is greater than 10; n is greater than 10; p is greater than 10; and a least one of R.sub.1, a, and b in mers I, II, and III is different than R.sub.1, a, and b in mers I, II, and III; (b) a drug present in the matrix; and (c) wherein the device when in operation bioerodes and releases drug at a controlled rate selected from (1) a zero order rate, (2) a continuous rate, and (3) a variable rate, which different rate is achieved by a preselected the terpolymer, the drug and the geometric shape forming the device.

### Claim 10 (depends on 1)

The drug eluting vascular graft of claim 1, wherein the graft comprises: (a) a matrix shaped, sized and adapted for placement in a human environment for administering drug thereto; (b) a multiplicity of microcapsules housed in the matrix with the microcapsules having a wall formed of a drug release rate controlling material, (c) a drug selected from the group consisting of locally and systemically acting therapeutic agents in the microcapsules; said matrix formed of a bioerodible drug release rate controlling pharmaceutically acceptable material, which material comprises a polymer of The formula ##STR3## wherein R.sub.1 is a member selected from the group of divalent, trivalent and tetravalent radicals consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; alkyleneoxy of 2 to 6 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene of 3 to 7 carbons substituted with an alkyl of 1 to 7 carbons, alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; cycloalkenylene of 4 to 7 carbons cycloalkenylene of 4 to 7 carbons substituted with an alkyl of 1 to 7 carbons, and alkoxy of 1 to 7 carbons, and alkylene of 1 to 10 carbons, and alkenyl of 2 to 7 carbons; arylene; and arylene substituted with an alkyl of 1 to 7 carbons, and alkoxy of 1 to 7 carbons, and alkenyl of 2 to 7 carbons; R.sub.2 and R.sub.3 are selected from the group consisting alkyl of 1 to 7 carbons; alkenyl of 2 to 7 carbons; alkoxy of 1 to 7 carbons; alkenyloxy of 2 to 7 carbons; alkylene of 2 to 6 carbons; alkenylene of 3 to 6 carbons; alkyleneoxy of 2 to 6 carbons; alkenyleneoxy of 3 to 6 carbons; aryloxy; aralkyleneoxy of 8 to 12 carbons; aralkenyleneoxy of 8 to 12 carbons; oxa; OR.sub.1 O with R.sub.1 as defined above; a heterocyclic ring of 5 to 8 carbon and oxygen atoms formed when R.sub.2 and R.sub.3 are taken together; a heterocyclic ring of 5 to 8 carbon and oxygen atoms substituted with an alkyl of 1 to 7 carbons, alkoxy of 1 to 7 carbons and alkenyl of 2 to 7 carbons formed when R.sub.2 and R.sub.3 are taken together; a fused polycyclic ring of 8 to 12 carbon and oxygen atoms formed when R.sub.2 and R.sub.3 are taken together; a fused polycyclic ring of 8 to 12 carbons and oxygen atoms substituted with an alkyl of 1 to 7 carbons; an alkoxy of 1 to 7 carbons and an alkenyl of 2 to 7 carbons; and wherein at least one of said R.sub.2 and R.sub.3 is a member selected form the group consisting of alkoxy, alkenyloxy and OR.sub.1 O; R.sub.2 and R.sub.3 when taken together are a member selected from the group of heterocyclic and fused polycyclic rings having at least one oxygen atom in the ring; and wherein n is greater than 10; (d) wherein, when the device is in operation, the matrix and the bioerode at a controlled and continuous rate over a prolonged period of time, thereby administering a therapeutically effective amount of drug to the patient at a controlled and continuous rate over a prolonged period of time.

### Claim 11 (depends on 1)

The drug eluting vascular graft of claim 1, wherein vascular graft comprises: (a) a matrix shaped, sized, and adapted for administering therapeutic agent to an animal, said matrix comprising multi layers formed of different bioerodible drug release rate controlling pharmaceutically acceptable materials, selected from materials which comprise a polymer of the formula: ##STR4## wherein R.sub.1 is a member selected from the group of divalent, trivalent and tetravalent radicals consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; alkyleneoxy of 2 to 6 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene of 3 to 7 carbons substituted with an alkyl of 1 to 7 carbons, alkylene of 1 to 10 carbons, and an alkenyl 2 to 7 carbons; cycloalkenylene of 4 to 7 carbons; cycloalkenylene of 4 to 7 carbons substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; arylene; and arylene substituted with an alkyl of 1 to 7 carbons, and alkoxy of 1 to 7 carbons, and an alkenyl of 2 to 7 carbons; R.sub.2 and R.sub.3 are selected from the group consisting of alkyl of 1 to 7 carbons; alkenyl of 2 to 7 carbons; alkoxy of 1 to 7 carbons; alkenyloxy of 2 to 7 carbons; alkylene of 2 to 6 carbons; alkenylene of 3 to 6 carbons; alkyleneoxy of 2 to 6 carbons; alkenyleneoxy of 3 to 6 carbons; aryloxy; aralkyleneoxy of 8 to 12 carbons; oxa; OR.sub.1 O with R.sub.1 as defined above; a heterocyclic ring of 5 to 8 carbon and oxygen atoms formed when R.sub.2 and R.sub.3 are taken together; a heterocyclic ring of 5 to 8 carbon and oxygen atoms substituted with an alkyl of 1 to 7 carbons; an alkoxy of 1 to 7 carbons and an alkenyl of 2 to 7 carbons formed when R.sub.2 and R.sub.3 are taken together; a fused polycyclic ring of 8 to 12 carbons and oxygen atoms formed when R.sub.2 and R.sub.3 are taken together; a fused polycyclic ring of 8 to 12 carbon and oxygen atoms substituted with an alkyl of 1 to 7 carbons, and alkoxy of 1 to 7 carbon and an alkenyl of 2 to 7 carbons; and wherein at least one of said R.sub.2 and R.sub.3 is a member selected from the group consisting of alkoxy, alkenyloxy and OR.sub.1 O; R.sub.1 and R.sub.3 when taken together are a member selected from the group of heterocyclic and fused polycyclic rings having at least one oxygen atom in the ring; and wherein n is greater than 10; (b) a therapeutic agent selected from the group consisting of locally and systemically acting pharmaceutically acceptable drugs present in the layers; and, (c) wherein, when the vascular graft is in operation, the layers bioerode at a controlled and continuous rate over a prolonged period of time, thereby administering a therapeutically effective amount of drug to the animal at a controlled and continuous rate over a prolonged period of time.

### Claim 12 (depends on 1)

A drug eluted vascular graft in claim 1, wherein the vascular graft comprises. (a) a matrix shaped, sized and adapted for administering therapeutic agent to an animal; (b) a plurality of discrete, closed cells in the matrix, said cells having a wall formed and defined by the matrix; said matrix formed of a bioerodible drug release rate controlling pharmaceutically acceptable material, which comprises a polymer of the formula: ##STR5## wherein R.sub.1 is a member selected from the group of divalent, trivalent and tetravalent radicals consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; alkyleneoxy of 2 to 6 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene of 3 to 7 carbons substituted with an alkyl of 1 to 7 carbons, and alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; cycloalkenylene of 4 to 7 carbons; cycloalkenylene of 4 to 7 carbons substituted with an alkyl of 1 to 7 carbons, and alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons, and alkenyl of 2 to 7 carbons; arylene; and arylene substituted with an alkyl of 1 to 7 carbons, and alkoxy of 1 to 7 carbons, and an alkenyl of 2 to 7 carbons; R.sub.2 and R.sub.3 are selected from the group consisting of alkyl of 1 to 7 carbons; alkenyl of 2 to 7 carbons; alkoxy of 1 to 7 carbons; alkenyloxy of 2 to 7 carbons; alkylene of 2 to 6 carbons; alkenylene of 3 to 6 carbons; alkyleneoxy of 2 to 6 carbons; alkenyleneoxy of 3 to 6 carbons; aryloxy; aralkyleneoxy of 8 to 12 carbons; aralkenyleneoxy of 8 to 12 carbons; oxa; OR.sub.1 O with R.sub.1 as defined above; a heterocyclic ring of 5 to 8 carbon and oxygen atoms formed when R.sub.2 and R.sub.3 are taken together; a heterocyclic ring of 5 to 8 carbon and oxygen atoms substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons and an alkenyl of 2 to 7 carbons formed when R.sub.2 and R.sub.3 are taken together; a fused polycyclic ring of 8 to 12 carbon and oxygen atoms formed when R.sub.2 and R.sub.3 are taken together; a fused polycyclic ring of 8 to 12 carbons and oxygen atoms substituted with an alkyl of 1 to 7 carbons, and alkoxy of 1 to 7 carbons and an alkenyl of 2 to 7 carbons; and wherein at least one of said R.sub.2 and R.sub.3 is a member selected form the group consisting of alkoxy, alkenyloxy and OR.sub.1 O; R.sub.2 and R.sub.3 when taken together are a member selected from the group of heterocyclic and fused polycyclic rings having at least one oxygen atom in the ring; an wherein n is greater than 10; (d) a therapeutic agent selected from the group consisting of locally and systemically acting pharmaceutically acceptable drugs present in the cells, said drug dissolved in a pharmaceutically acceptable carrier that is a solvent for the drug and a nonsolvent for the polymer; and, (e) wherein, when in operation, the vascular graft bioerodes at a controlled and continuous rate over a prolonged period of time, thereby administering a therapeutically effective amount of drug in the carrier to the animal at a controlled and continuous rate over a prolonged period of time.

### Claim 13 (depends on 1)

The drug eluted vascular graft of claim 1, where in the vascular graft comprises: (a) a matrix shaped, sized and adapted for administering drug to an animal, which matrix is a multilayered with the layer formed oaf a bioerodible drug released rate controlling pharmaceutically acceptable material, said material selected form and comprising a polymer fo the formula: ##STR6## wherein R.sub.1 is a member selected from the group of divalent, trivalent, and tetravalent radicals consisting of alkylene 1 to 10 carbons; alkenylene of 2 to 10 carbons; alkyleneoxy of 2 to 6 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene of 3 to 7 carbons substituted with an alkyl of 1 to 7 carbons, alkoxy of 1 to 7 carbons, and alkylene of 1 to 10 carbons, and an alkenyl of 2 to 7 carbons; cycloalkenylene of 4 to 7 carbons; cycloalkenylene of 4 to 7 carbons substituted with an alkyl of 1 to 7 carbons, and alkoxy of 1 to 7 carbons, an alkylene of 1 to 10 carbons, and alkenyl of 2 to 7 carbons; arylene; and arylene substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons, and an alkenyl of 2 to 7 carbons; R.sub.2 and R.sub.3 are selected from the group consisting of alkyl of 1 to 7 carbons; alkenyl of 2 to 7 carbons; alkoxy of 1 to 7 carbons; alkenyloxy of 2 to 7 carbons; alkylene of 2 to 6 carbons; alkenylene of 3 to 6 carbons; alkyleneoxy of 2 to 6 carbons; alkenyleneoxy of 3 to 6 carbons; aryloxy; arakyleneoxy of 8 to 12 carbons; aralkenyleneoxy of 8 to 12 carbons; oxa; OR.sub.1 O with R.sub.1 as defined above; a heterocyclic ring of 5 to 8 carbons and oxygen atoms formed when R.sub.2 and R.sub.3 are taken together; a heterocyclic ring of 5 to 8 carbon and oxygen atoms substituted with an alkyl of 1 to 7 carbons, an alkoxy of 1 to 7 carbons and an alkenyl of 2 to 7 carbons formed when R.sub.2 and R.sub.3 are taken together; a fused polycyclic ring of 8 to 12 carbon and oxygen atoms formed when R.sub.2 and R.sub.3 are taken together; a fused polycyclic ring of 8 to 12 carbon and oxygen atoms substituted with an alkyl of 1 to 7 carbons, and alkoxy of 1 to 7 carbons and an alkenyl of 2 to 7 carbons; and wherein at least one of said R.sub.2 and R.sub.3 is a member selected from the group consisting of alkoxy, alkenyloxy and OR.sub.1 O; R.sub.2 and R.sub.3 when taken together are a member selected from the group of heterocyclic and fused polycyclic rings having at least one oxygen atom in the ring; and wherein n is greater than 10; (b) a plurality of discrete, closed cells in at least one layer; (c) a drug selected from the group consisting of locally and systemically acting therapeutically acceptable drugs mixed with a pharmaceutically acceptable carrier housed in the cells; and (d) wherein, when in operation, the vascular graft bioerodes at a controlled and continuous rate over a prolonged period of time, thereby administering a therapeutically effective amount of drug mixed with the carrier to the animal at a controlled and continuous rate over a prolonged period of time.

### Claim 14 (depends on 1)

The drug eluted vascular graft of claim 1, wherein said vascular graft may contain a erosion rate modifier.

### Claim 15 (depends on 1)

The drug eluting vascular graft of claim 1, wherein said therapeutic agent is selected from a group consisting of:
a). Antimicrotuble agent such as paclictaxel, docetaxel.
b). Antiproliferative agent such as cyclophosphamide, actinomycin-D, cis-platinum, mitomycin, methotrexate, azithioprim.
c). Immunosupressive agent such as sirolimus, cyclosporine A, or steroid such as dexamethasone or methylprednisolone.
d). A glycoprotein IIb/IIIa receptor inhibitor such as abciximab, eptifibatide, tirofiban, sibrafiban, xemilofiban, orbofiban, roxifiban, lotrabian.
f). A platelet aggregation inhibitor such as clopidogrel or ticlopidine.
g). A nitric oxide donor such as nitroglycerin, isosorbide dinitrate, or ntiroprusside.
h). A calcium channel blocker (verapamil, diltiazem, nifedipine, etc.).
I). An antithrombogenic agent (heparin, low molecular weight heparin, hirudin).
J). An anti-sense nucleic acid.
k). A thiazolidinedione.
l). A HMG Co A reductase inhibitor such as pravastatin.
m). An angiotensin converting enzyme inhibitor.
n). A omega 3 fish oil.

### Claim 16

The drug eluting vascular graft in claim one, wherein microcapsules of said therapeutic agents are dispersed within said polymers.

### Claim 17 (depends on 1)

The drug eluting vascular graft of claim 1, wherein said microcapsules have a wall formed of a drug release rate controlled material so that said microcapsules are released in a controlled and continuous rate over a prolonged period of time.

### Claim 18

A method for preventing or thrombosis of vascular grafts.

### Claim 19

A method for preventing stenosis of vascular grafts.

### Claim 20

An improved vascular graft used in vascular access for hemodialysis.

### Claim 21

An improved vascular graft used in vascular reconstruction.

### Claim 22

An improved vascular graft used in the treatment of coronary artery disease.
